CU23552A1 - Composición vacunal - Google Patents

Composición vacunal

Info

Publication number
CU23552A1
CU23552A1 CU20040285A CU20040285A CU23552A1 CU 23552 A1 CU23552 A1 CU 23552A1 CU 20040285 A CU20040285 A CU 20040285A CU 20040285 A CU20040285 A CU 20040285A CU 23552 A1 CU23552 A1 CU 23552A1
Authority
CU
Cuba
Prior art keywords
meningococcal
vesicle
serosubtype
country
derived
Prior art date
Application number
CU20040285A
Other languages
English (en)
Inventor
Jan Poolman
Pierre Michel Desmons
Alvarez Francisco Jesus Dominguez
Morales Ramon Faustino Barbera
Original Assignee
Glaxosmithkline Biolog Sa
Inst Finlay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Inst Finlay filed Critical Glaxosmithkline Biolog Sa
Publication of CU23552A1 publication Critical patent/CU23552A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención está relacionada con compuestos vacunales para la prevención o tratamiento efectivos de la enfermedad, preferiblemente meningocóccica, provocada por Neisseria. Las vacunas de la invención forman un compuesto multivalente de vesícula meningocóccica que comprende por lo menos una vesícula con actividad bactericida homóloga que se deriva de una cepa meningocóccica con un serosubtipo (inmunotipo PorA) que prevalece en el país de uso, y al menos una vesícula con actividad bactericida heteróloga que se deriva de una cepa meningocóccica que no necesita tener un serosubtipo que prevalezca en el país de uso.
CU20040285A 2002-06-13 2004-12-10 Composición vacunal CU23552A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation

Publications (1)

Publication Number Publication Date
CU23552A1 true CU23552A1 (es) 2010-07-20

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20040285A CU23552A1 (es) 2002-06-13 2004-12-10 Composición vacunal

Country Status (20)

Country Link
US (1) US20060110412A1 (es)
EP (1) EP1565211A2 (es)
JP (1) JP2005531614A (es)
KR (1) KR20050049431A (es)
CN (1) CN100387298C (es)
AR (1) AR040204A1 (es)
AU (1) AU2003236734A1 (es)
BR (1) BR0311777A (es)
CA (1) CA2488782A1 (es)
CL (1) CL2003001192A1 (es)
CU (1) CU23552A1 (es)
GB (1) GB0213622D0 (es)
MX (1) MXPA04012568A (es)
NO (1) NO20050132L (es)
NZ (1) NZ560766A (es)
PE (1) PE20040562A1 (es)
RU (1) RU2005100509A (es)
UY (1) UY27843A1 (es)
WO (1) WO2003105890A2 (es)
ZA (1) ZA200409547B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009643A2 (en) 2000-07-27 2002-02-07 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
TR201900418T4 (tr) * 2005-12-22 2019-02-21 Glaxosmithkline Biologicals Sa Pnömokok polisakkarit konjugat aşısı.
CA2662051A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
MX340096B (es) 2007-10-19 2016-06-27 Glaxosmithkline Biologicals Sa Formulaciones de vacuna meningococica.
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
WO2009094779A1 (en) * 2008-02-01 2009-08-06 Sanofi Pasteur Limited Assay for diagnosing streptococcus pneumoniae
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
JP2013503148A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US8691522B2 (en) * 2009-10-08 2014-04-08 Aeon Medix Inc. Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (pt) 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
JP5894083B2 (ja) * 2009-12-22 2016-03-23 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物
MX2012010609A (es) 2010-03-18 2012-10-03 Novartis Ag Vacunas adyuvadas para meningococos serogrupo b.
EP2549990A1 (en) 2010-03-23 2013-01-30 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
HUE040658T2 (hu) 2010-04-07 2019-03-28 California Inst Of Techn Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek
ES2759484T3 (es) * 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
AU2013214105A1 (en) 2012-02-02 2014-07-24 Novartis Ag Promoters for increased protein expression in meningococcus
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
EP2861247B1 (en) 2012-06-14 2020-12-09 GlaxoSmithKline Biologicals SA Vaccines for serogroup x meningococcus
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
JP2023546665A (ja) * 2020-10-23 2023-11-07 オームヴァックス，インコーポレイテッド． 淋菌（Ｎｅｉｓｓｅｒｉａ Ｇｏｎｏｒｒｈｏｅａｅ）に対するワクチン接種のための組成物及び方法
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1272062A (zh) * 1997-07-17 2000-11-01 北美疫苗公司 含有b组脑膜炎球菌膜孔蛋白和流感嗜血菌多糖的免疫偶联物
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
WO2002009643A2 (en) * 2000-07-27 2002-02-07 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Also Published As

Publication number Publication date
NZ560766A (en) 2009-09-25
CN100387298C (zh) 2008-05-14
JP2005531614A (ja) 2005-10-20
NO20050132L (no) 2005-02-11
GB0213622D0 (en) 2002-07-24
NO20050132D0 (no) 2005-01-11
KR20050049431A (ko) 2005-05-25
UY27843A1 (es) 2003-12-31
AU2003236734A1 (en) 2003-12-31
US20060110412A1 (en) 2006-05-25
EP1565211A2 (en) 2005-08-24
WO2003105890A3 (en) 2004-03-25
CA2488782A1 (en) 2003-12-24
RU2005100509A (ru) 2006-06-10
WO2003105890A2 (en) 2003-12-24
PE20040562A1 (es) 2004-10-19
CN1668329A (zh) 2005-09-14
BR0311777A (pt) 2005-03-29
CL2003001192A1 (es) 2005-01-07
MXPA04012568A (es) 2005-09-21
AR040204A1 (es) 2005-03-16
ZA200409547B (en) 2006-07-26

Similar Documents

Publication Publication Date Title
CU23552A1 (es) Composición vacunal
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
BR0112928A (pt) Vacinas para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
AR109170A2 (es) Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente
EA200901161A1 (ru) Вакцина против гриппа в виде эмульсии типа "масло в воде"
CL2007001698A1 (es) Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis.
BRPI0510430A (pt) composições e métodos para vacinação mucosal
CL2016000650A1 (es) Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
CY1118629T1 (el) Εμβολιο ιου ερπητα ζωστηρα
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
BRPI0607374B8 (pt) vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
BR122017018225A8 (pt) Composição fungicida, seus usos, agente fungicida, método para controlar fungos nocivos fitopatogênicos, e semente resistente a fungos nocivos fitopatogênicos
CY1111471T1 (el) Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
PE20190458A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
NO20062918L (no) Anvendelse av antibiotika som vaksineadjuvanser
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
BRPI0014142B8 (pt) composição de vacina comprimida estável, e, pacote para vacinação
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
NO20075206L (no) Medisinske sammensetninger av salter, chelatorer og/eller frie syrer av alfa hydroksyl organiske syrer samt relaterte prosesser og fremgangsmater
AR056712A1 (es) Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus

Legal Events

Date Code Title Description
FG Grant of patent